Poly-alanine (Ala) tract expansions in transcription factors have been shown to be associated with human birth defects such as malformations of the brain, the digits, and other structures. Expansions of a poly-Ala tract from 15 to 22 (17) -29 (114) Ala in Hoxd13, for example, result in the limb malformation synpolydactyly in humans and in mice [synpolydactyly homolog (spdh)]. Here, we show that an increase of the Ala repeat above a certain length (22 Ala) is associated with a shift in the localization of Hoxd13 from nuclear to cytoplasmic, where it forms large amorphous aggregates. We observed similar aggregates for expansion mutations in SOX3, RUNX2 and HOXA13, pointing to a common mechanism. Cytoplasmic aggregation of mutant Hoxd13 protein is influenced by the length of the repeat, the level of expression and the efficacy of degradation by the proteasome. Heat shock proteins Hsp70 and Hsp40 co-localize with the aggregates and activation of the chaperone system by geldanamycin leads to a reduction of aggregate formation. Furthermore, recombinant mutant Hoxd13 protein forms aggregates in vitro demonstrating spontaneous misfolding of the protein. We analyzed the mouse mutant spdh, which harbors a 17 Ala expansion in Hoxd13 similar to the human synpolydactyly mutations, as an in vivo model and were able to show a reduction of mutant Hoxd13 and, in contrast to wt Hoxd13, a primarily cytoplasmic localization of the protein.
INTRODUCTION
Trinucleotide repeat expansions are a common cause of disease. In principle, they can be categorized into two subclasses: those that have their repeats in non-coding sequences and those characterized by exonic repeats. Expansions of (CAG)n repeats that code for polyglutamine (poly-Q) tracts have been shown to be the basis of several human diseases, characterized by progressive neuronal dysfunction that typically begins in mid-life and results in severe neurodegeneration (1) . Consequences of hyperexpansion of DNA-triplet repeats might include altered rates of transcription or translation, mRNA instability and aberrant hairpin structures (2) . The expanded protein repeat is thought to destabilize the native configuration of the mutant protein resulting in the formation of aggregates within the cell. Although other amino acid repeats besides poly-Q are common in the human genome (3), few have been associated with disease.
Recently, poly-alanine (Ala) tract expansions have been described as the causative defect in several conditions (4) . To date, nine human conditions, including synpolydactyly (SPD) type II (HOXD13) (OMIM 186000) (5), cleidocranial dysplasia (RUNX2) (OMIM 119600) (6) , holoprosencephaly type 5 (ZIC2) (OMIM 603073.0003) (7), hand -foot -genital syndrome (HOXA13) (OMIM 140000) (8) , blepharophimosis epicanthus inversus syndrome (FOXL2) (OMIM 110100) (9) , mental retardation with growth hormone deficiency (SOX3) (OMIM 300123) (10) , Partington syndrome (ARX) (OMIM 309510) (11) , congenital central hypoventilation syndrome (PHOX2B) (OMIM 209880) (12) and oculopharyngeal muscular dystrophy (OPMD) (PABPN1) (OMIM 164300) (13), have been described. With the exception of PABPN1, a poly-A binding protein, all mutated genes code for transcription factors with important roles during development and differentiation. The length of the normal Ala tract is similar in all transcription factors (14 -20 Ala residues), and so is Human Molecular Genetics, Vol. 13 2351-2359 doi:10.1093/hmg/ddh277 Advance Access published on August 27, 2004 the expanded tract that causes disease (18 -29 Ala residues), suggesting a common underlying mechanism. Poly-Ala repeats are meiotically stable and thus differ sharply from the dynamic expansions underlying conditions such as Huntington's disease or myotonic dystrophy. Furthermore, in contrast to other trinucleotide expansion diseases that cause late onset neurodegenerative conditions, poly-Ala expansions in transcription factors result in congenital defects. Thus, the underlying mutational mechanisms as well as the pathogenesis of poly-Ala repeat associated conditions appears to be distinct from poly-Q tract expansions. However, the pathogenic mechanism of Ala repeat expansions remains unknown.
Ala expansions (þ7 to þ14 Ala in addition to the 15 Ala in wt) in HOXD13 were the first mutations of this kind described (5) . They result in a distinct hand malformation phenotype, SPD, a dominant condition characterized by syndactyly of fingers 3 and 4, with an additional finger in the polydactylous web. In a previous study, we could show that the length of the Ala-expansions correlates with severity and penetrance of the phenotype (14) . Individuals with short repeats, i.e. þ7 Ala, show considerable intra-familial and also intra-individual variability, whereas those with long expansions, i.e. þ10 Ala and more, have a more severe and completely penetrant phenotype. The mechanisms by which these repeats cause pathology are unknown but studies in mice with similar expansions in Hoxd13 suggest a dominant negative effect (15) . Likewise, inactivation of Hoxd13 in the mouse results in a rather mild phenotype not comparable with SPD, whereas inactivation of Hoxd11, Hoxd12 and Hoxd13 together results in a SPD-like malformation (16) .
In this study, we aimed at identifying the molecular mechanisms behind the poly-Ala expansions in Hoxd13. Furthermore, we wanted to know whether the poly-Ala expansions in other transcription factors follow similar mechanisms resulting in a common pathogenetic cause. Our results show that an increase in the length of the poly-Ala repeat beyond a certain threshold results in cytoplasmic aggregation and degradation of the mutant protein, thus preventing nuclear localization and normal function of the transcription factor.
RESULTS

Mutant Hoxd13 accumulates in the cytoplasm
To investigate the mechnisms of Ala repeat expansion mutations, we made a series of constructs containing wt Hoxd13 (15 Ala), Hoxd13 with a very short Ala repeat (2 Ala) and Hoxd13 with expanded Ala repeats of varying length, similar to those observed in SPD patients. The size of the Ala repeat is indicated as the number of Ala residues in addition (þ) to the 15 alanines in wt. These constructs were transiently expressed in Cos-1 cells and analyzed 40 h later by fluorescence microscopy. We observed the formation of large cytosolic aggregates, a finding that was most pronounced in cells transfected with the long expansions (Fig. 1A) . In contrast, cells expressing the wt or the mutant containing only 2-Ala showed an exclusively nuclear localization. We analyzed the aggregates using electron microscopy and immunogold labeling (Fig. 1B) . Wt Hoxd13 was found in the nucleus, mainly in the periphery in areas of chromatin condensations. In contrast, in cells expressing mutant Hoxd13 (þ14 Ala) loose aggregates were observed in the cytoplasm that showed labeling for Hoxd13. These aggregates consisted of dense and more electron lucent areas that did not appear to have a higher structural order and were thus distinct from those observed in poly-Q disease associated aggregates such as Huntington's disease. Labeling for the mutant Hoxd13 protein was observed only in the electron dense areas.
We compared the localization of the protein between the different mutants by cell counting, performed by two independent investigators. In the majority of cells expressing the short expansions, i.e. þ7 Ala and þ8 Ala, Hoxd13 localized to the nucleus. The þ9 variant showed nuclear localization in only 50%, and in cells expressing the longest expansions, i.e. þ14 Ala and þ21 Ala, the mutant protein was almost exclusively found in the cytoplasm (Fig. 1C) . Thus, expansions of the Ala repeat in the N-terminal domain of Hoxd13 result in aggregation of the protein in cytoplasmic inclusions, a process that appears to prevent Hoxd13 from entering the nucleus. Cytoplasmic aggregation occurs beyond a threshold of repeat length [22 (þ7) Ala] and increases with the repeat length.
Wt Hoxd13 co-localizes with mutant protein in aggregates
To study the interaction of mutant on wt Hoxd13, we coexpressed both wt and þ14 Ala in Cos-1 cells. The results show co-localization of mutant and wt protein in the aggregates indicating that the mutation prevents the wt protein from entering the nucleus (Fig. 1D ). This finding may partly explain the dominant character of the Ala expansion mutations. However, the observed interaction appears to be limited to wt Hoxd13 as other Hox genes that are normally co-expressed with Hoxd13 in the limbs, i.e. Hoxd11, Hoxd12 or Hoxa13 are not influenced and readily translocate into the nucleus (Fig. 1E ).
Other transcription factors such as Runx2 were also not affected. The Ala repeat appears not to be the critical region of interaction as the 2 Ala mutant is also retained. Thus, in vitro the result of the repeat expansion is compatible with a dominant negative effect but there is no influence on the cellular localization of other Hox-genes.
Aggregate formation in other poly-Ala expansion mutations
Poly-Ala expansion diseases are a growing group of disorders that are characterized by abnormal development. Given the similarity between the HOXD13 and the other poly-Ala repeat diseases, we asked the question whether these conditions may follow a similar pathology. We cloned wt and mutant of RUNX2 [þ10 Ala mutant (6)], HOXA13 (þ11 Ala, unpublished case with hand -foot -genital syndrome) and SOX3 [þ11 Ala (10) ] and expressed them in Cos-1 cells. We obtained the same results as for the Hoxd13 mutants. The Ala expansion mutant was completely retained in the cytoplasm, whereas the wt was located in the nucleus (Fig. 1F) . Similar to Hoxd13, co-expression of the mutant together with the wt protein resulted in retention of the wt in the aggregate. This indicates that the above-described mechanisms may be a general one explaining not only Hoxd13 mutations but also other Ala expansion mutations.
Mutant Hoxd13 does not locate to the aggresome
Misfolded proteins have been shown to accumulate at a specific site in the cells around the microtubule-organizing center (MTOC), where they get degraded by the proteasome. One consequence of aggresome formation is the rearrangement of components of the intermediate filament cytoskeleton such as vimentin (17, 18) . Vimentin is a common component of the filament, normally forming a delicate array of peripheral fibers. Overexpression of GFP250, for example, results in rapid aggregate formation within the MTOC and in drastic collapse of vimentin intermediate filaments in a 'cage-like' structure around the aggregate (17, 18) . Formation of the Hoxd13 aggregate, however, does not result in the displacement of vimentin in contrast to the dense aggregates at the MTOC associated with overexpression of, for example, GFP-250 ( Fig. 2A ). Hoxd13 aggregates are loosely arranged protein clumps surrounding the nucleus (Fig. 2B ). Co-staining with g-tubulin showed that the bulk of Hoxd13 aggregates localized in the area of the MTOC, but we did not observe co-localization with g-tubulin and vimentin, as observed with GFP-250. Furthermore, the Golgi apparatus which is in close proximity to the MTOC as well as the 20S proteasome subunit which is recruited to the MTOC did not co-localize with the Hoxd13 aggregates ( Fig. 2C and D) . These results indicate that Hoxd13 associated aggregates are different from those classically associated with aggresome formation.
Involvement of chaperones in aggregate formation
The folding of newly synthesized proteins to their proper conformations involves chaperones such as heat shock proteins (Hsp) which also play a role in the recognition of misfolded proteins. Moreover, Hsp70 and Hsp40 can catalyze the refolding of denatured or partially denatured molecules into active forms and are able to disassemble intracellular protein aggregates into soluble native species (19) . We were able to demonstrate co-localization of Hsp40 and Hsp70 with the aggregated protein indicating that both proteins are recruited to the perinuclear aggregates (Fig. 2E) . Treatment of cells with geldanamycin, a naturally occurring tumor drug that interacts with Hsp90, results in an up-regulation of Hsp40 and Hsp70 (20) . We found that treatment of Hoxd13 (þ14 Ala) transfected cells with geldanamycin results in a drastic reduction of aggregate formation and a consecutive increase in nuclear localization (Fig. 2F ), indicating that Hsps, when activated early in the aggregation process, can slow down the perinuclear (Fig. 2G) . Similar results were obtained for two other more specific proteasome inhibitors, MG132 and lactacystin. Thus, at low production rates, the mutant protein can be efficiently degraded via the proteasome.
Mutant Hoxd13 aggregates in vitro
To investigate the effect of the poly-Ala expansion on the native Hoxd13 protein, we produced recombinant wt Hoxd13 and mutant protein with a þ21 Ala expansion. Using a filter precipitation assay, we can show that the mutant but not the wt protein spontaneously forms aggregates (Fig. 3) . This indicates that the poly-Ala expansion is necessary and sufficient for aggregation of the protein.
Mutant Hoxd13 is retained in the cytoplasm and degraded in vivo
To test whether the effects observed in vitro are also of relevance in vivo, we investigated the localization of wt and mutant Hoxd13 protein in wt and synpolydactyly homolog (spdh) mutant mice. Spdh is a recessive mouse mutant with a þ7 Ala expansion in Hoxd13 identical to the expansions observed in patients with SPD (22) . The mutant phenotype is similar to the human phenotype consisting of polydactyly, syndactyly and brachydactyly. The mice show a reduction in proliferation of cells in the autopod, a finding that may in part explain the shortening of the digits (23) . We analyzed the distribution of Hoxd13 protein using a Hoxd13 antibody (24) in E13.5 wt limbs and found a distribution of Hoxd13 similar to that of Hoxd13 mRNA. Positive cells showed a predominantly nuclear staining. In contrast, the overall signal was much weaker in spdh/spdh mice, suggesting a significant reduction in the amount of Hoxd13 protein (Fig. 4B) . Furthermore, distribution of the protein was abnormal with stronger staining in the cytoplasm than in the nucleus. In areas of high Hoxd13 expression, i.e. around the cartilaginous anlagen, some cells showed accumulated cytoplasmic staining (Fig. 4D ). Western blot (WB) analysis of Hoxd13 protein in wt, spdh/þ and spdh/spdh limbs showed a reduction by 50% in the heterozygous and by 90% in the homozygous animals ( Fig. 4E) , thus confirming our immunohistochemical findings.
Poly-Ala tracts are associated with nuclear proteins and have a maximal length of 20
Poly-Ala tracts are not uncommon in the human genome. To find a possible association between Ala tracts, gene function and mechanisms of disease, we performed a genome-wide search based on Swiss-Prot and TrEMBL for poly-Ala tracts longer than 8 Ala. We identified 137 proteins of which seven could not be assigned to any functional category. Of the remaining 130 proteins, 102 (77%) were described to be located in the nucleus and 32 (23%) were cytoplasmic, membrane bound, or extracellular proteins. Of the nuclear proteins, 66 (50% of total) were transcription factors. The relative percentage of transcription factors increased with the length of the repeat. The longest repeat consisting of 20 Ala was found in PHOX2B, the transcription factor mutated in congenital central hypoventilation syndrome. The results indicate that Ala repeats are likely to have a function related to the nucleus and thus in the regulation of transcription.
DISCUSSION
Our results indicate a common pathogenetic mechanism for poly-Ala repeat expansions in transcription factors. Expansions of the repeat beyond a certain threshold appear to result in degradation of the protein and/or, dependent on the efficacy of degradation, the level of expression and the length of the Ala-repeat, cytoplasmic aggregation. First, the mutant protein is translocated into the nucleus, but prolonged exposure of the cell results in the formation of small aggregates that subsequently form large inclusions around the nucleus. These inclusions appear to capture mutant and wt protein, thus preventing it from reaching its destination, the nucleus. Similar to our in vitro results, we could show in a previous clinical study that the length of the Ala expansion correlates with the severity and penetrance of the SPD phenotype (14) . Individuals with short repeats, i.e. þ7 Ala, show considerable intra-familial and also intra-individual variability and low penetrance, whereas those with long expansions, i.e. þ10 Ala and more, have a more severe phenotype with complete penetrance. This scenario is likely to apply also to other poly-Ala repeat diseases. The strong association of long (.10) Ala repeats with nuclear proteins suggests a function related to the nucleus and thus regulation of transcription. In previous studies, Ala tracts have been shown to be necessary for transcription factor activity (25) . The fact that no repeats longer than 20 Ala were found in our Swiss-Prot and Trembl search and that the length of the repeat is highly constant indicates a evolutionary constraint on the repeat length. This is in agreement with the clinical observation that the shortest repeat to give rise to SPD is 22 (þ7) Ala long and that other transcription factor associated poly-Ala expansions are of similar size. In addition, our in vitro results demonstrate a similar threshold. It thus appears likely that an increase of Ala repeat length The discrimination between native and non-native proteins involves a quality control that primarily depends on chaperones (19) . This quality control can take place in the cytosol or in the endoplasmic reticulum (ER). Terminally misfolded proteins are recognized within the ER and 'retrotranslocated' across the ER membrane and ubiquitinated to be degraded by cytosolic proteasomes. If production exceeds degradation, distinct perinuclear inclusion bodies will form that contain the mutant protein. These inclusions are located at a specific site of the cell around the centrosome/the MTOC (17, 18) as shown by colocalization of the aggresome with g-tubulin (an established centrosome marker) and vimentin. At high levels of misfolded proteins, these structures expand and recruit the cytosolic pools of ubiquitin, the HSP70 and the 20S proteasome (26) . Together these findings suggest that mammalian cells contain a specific organelle, which subsequently has been named 'aggresome', that specializes in the degradation of misfolded proteins (17) . Our results indicate that Hoxd13 aggregates are different from those classically associated with aggresome formation as we do not find involvement of the vimentin intermediate filaments, no localization of the aggregates at the MTOC and no co-localization with the 20S proteasome subunit. A possible explanation is that Hoxd13, as other transcription factors, is translated in the cytoplasm by free ribosomes, and thus does not involve endoplasmic reticulum associated degradation (ERAD). However, similar structures have been observed in cells overexpressing GFP -GCP170, a GFPtagged Golgi protein (18) , indicating that this phenomenon is not restricted to proteins with poly-Ala expansions.
Aggregation of misfolded proteins has been described in conditions associated with repeat expansions of poly-Q encoding tracts (1) . In contrast to the congenital conditions discussed here, they lead to progressive neuronal dysfunction and severe neurodegeneration typically beginning in mid-life. Likewise, expansions of a short Ala repeat from 8 Ala to 11-17 Ala in PABNP1, a gene coding for a poly-A binding molecule, result in the neurological phenotype OPMD, a condition characterized by late onset progressive muscular weakness. Similar to the poly-Q associated conditions, such as Huntington's disease, OPMD patients show characteristic nuclear inclusions composed of tubular filaments that are often arranged in palisades or tangles (13, 27) . In contrast, electron microscopy (Fig. 1B) of the inclusions associated with Hoxd13 overexpression show amorphous material consisting of dense and more electron lucent areas that does not appear to follow a higher structural order. The differences in onset, pathology and clinical presentation argue that the pathogenesis of PABNP1 mutations is similar to other neurological repeat expansion diseases and thus different from polyAla expansions in transcription factors that are predominantly associated with developmental defects.
In several poly-Ala associated conditions, other mutations such as deletions, non-sense mutations or frameshifts have been described suggesting that the phenotype can be caused by a loss of protein function. In these cases, Ala repeat expansions are likely to result in efficient degradation of the misfolded protein by the proteasome and thus a non-functional protein. In other conditions such as SPD (5), cleidocranial dysplasia (6) and hand -foot -genital syndrome (8), however, there appears to be a dominant negative effect of the mutations resulting in additional or more pronounced phenotypes. For example, inactivation of Hoxd13 in the mouse causes a rather mild phenotype which is distinct from SPD, whereas inactivation of Hoxd11, Hoxd12 and Hoxd13 together result in a SPD-like malformation (16) . This finding and genetic complementation experiments in the mouse mutant spdh suggested a negative effect of mutant Hoxd13 over other Hox genes (15) . Our in vitro results show that the repeat expansion is unlikely to have a specific effect on other Hox genes. Instead, the presence of small amounts of mutant Hoxd13 in the cytoplasm of spdh/spdh mice suggests inefficient degradation of the mutant protein and an overload of the cell's degradative capacity. This effect can be expected to be more pronounced in repeats that are longer than the 
MATERIALS AND METHODS
Plasmid construction
The mouse Hoxd13, Hoxd12 and Hoxd11 genes were amplified by RT -PCR and cloned into pTL1-HA and pTL10-Flag (21) . The þ7 Ala construct was amplified by PCR using DNA from the spdh mouse mutant as template. All other Ala constructs (þ8, þ9, þ10, þ14 and þ21) were cloned by inserting an oligo consisting of the additional alanines into the Not I site inside the Ala-coding repeat of the mouse Hoxd13 gene. For the Hoxa13 constructs, exon 1 was PCR amplified from DNA of a patient with a heterozygous þ11 Ala mutation, ligated to the RT -PCR amplified mouse exon 2 and cloned into pTL1-HA. The Ala repeat of human RUNX2 was PCR amplified from a patient harboring a þ10 Ala expansion and inserted into the coding sequence of mouse Runx2 in pTL-HA. The human Sox3 gene was PCR amplified from a patient with a heterozygous þ11 Ala mutation and cloned into pTL1-HA and pTL10-Flag. The mouse Hoxd13 wt and þ14 Ala constructs were cloned into the RCAS-BPA-vector. Virus production was done as described previously (21) .
Cell lines and cell transfection
Cos-1 cells were grown in Dulbecco's modified Eagle's medium high glucose supplemented with 5% fetal calf serum and containing penicillin (100 U/ml) and streptomycin (100 mg/ml). Transfection was performed using PolyFect (Qiagen) according to manufacturer's instruction. After 16 h, the medium was removed and fresh medium was added.
The cells were washed with PBS and fixed with 4% PFA 40 h after transfection. Geldanamycin (InvivoGen) was used as described previously (20) . DF-1 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2% fetal chicken serum and containing penicillin (100 U/ml) and streptomycin (100 mg/ml). Cells were infected with RCAS virus containing Hoxd13 wt and Hoxd13 þ14 Ala. For inhibition of the proteasome activity after infection, cell cultures were adjusted to 25 mM Calpain Inhibitor I (ALLN, Sigma) and incubated for an additional 24 h. Control cells were incubated with an equivalent amount of DMSO.
Immunofluorescence and microscopy
Cos-1 cells grown on coverslips were fixed 40 h after transfection with 4% paraformaldehyde for 10 min at room temperature. Cells were permeabilized with 0.2% Triton X-100 in PBS and incubated with primary antibody diluted in PBS, 10% FCS and 0.05% NaN 3 for 1 h at room temperature. Secondary antibodies were diluted in PBS, 10% FCS and 0.05% NaN 3 and incubated on coverslips for 1 h at room temperature. The cells were washed and nuclei were counterstained with DAPI. The coverslips were mounted on slides in Fluoromount-G (Electron Microscopy Sciences). The samples were examined with a fluorescence microscope Axiovert-200 (Zeiss). For the g-tubulin-antibody, the cells were fixed and permeabilized with ice-cold methanol for 10 min at 2208C.
For electron microscopy, COS-1 cells were fixed and embedded in LR White (London Resin Company) 40 h after transfection. Post-embedded immunogold labeling was performed as described using the rabbit-anti-HA antibody (1 : 80) followed by secondary antibody conjugated with 10 nm gold (1 : 100; British Bio Cell). The samples were viewed in a Philips CM 100 electron microscope.
For immunofluorescence (IF) on mouse tissues, E13.5 limb buds were paraformaldehyde fixed, paraffin embedded and serial sections of 6 mm were cut. Two different primary antiHoxd13 antibodies (24) were applied to the dewaxed sections, washed and the signal detected by AlexaFluor 488 goat-antirabbit IgG.
Antibodies
The following antibodies were used for IF and/or WB analyses: mouse anti-HA (Sigma), rabbit anti-HA (Sigma), mouse anti-Flag (Sigma) and rabbit anti-Flag (Sigma) were diluted 1 : 250 (IF), mouse anti-vimentin (Sigma) was diluted 1 : 400 (IF), mouse anti-g Tubulin (Sigma) was diluted 1 : 100 (IF), goat-anti-Hsp40 and goat-anti-Hsp70 (Santa Cruz Biotechnology) were diluted 1 : 50 (IF), anti-Golgi (anti-g-adaptin) was diluted 1: 300, anti-11S (Affiniti) was diluted 1 : 250, anti-proteasome 20S a-Type 1 subunit (Calbiochem) was diluted 1 : 60 (IF), rabbit anti-Hoxd13 (a generous gift from Atsushi Kuroiwa) was diluted 1 : 8000 (WB), rabbit anti-actin (Sigma) was diluted 1 : 8000 (WB), peroxidase goat-anti-rabbit IgG (Oncogene) was diluted 1: 2000 (WB), AlexaFluor 546 goat-anti-rabbit IgG, AlexaFluor 546 goat-anti-mouse IgG, AlexaFluor 488 goat-anti-rabbit IgG, AlexaFluor 488 goat-anti-mouse IgG, AlexaFluor 488 donkey-anti-goat IgG and AlexaFluor 546 donkey-anti-rabbit IgG (Molecular Probes) were diluted 1 : 500 (IF).
Western blot
The Hoxd13-expressing limb-tissue of three embryos of embryonic stage E13.5 were pooled in 4 mM HEPES -NaOH pH 7.4 and 320 mM sucrose. Proteinase-inhibitor (Complete Mini, Roche) and b-mercaptoethanol (10 mM) were added and the limbs lysed on ice in 1.5 ml tubes using a rotary homogenizer. The protein concentration was estimated using the BioRad microassay procedure (Bradford method) with BSA as standard. Ten micrograms of total protein per lane was loaded on a 12.5% SDS -PAGE and run for 2 -3 h at 40 mA. SDS -PAGE-separated samples were transferred to Immobilon PVDF membrane and analyzed by immunoblotting with an anti-Hoxd13 antibody. To remove primary and secondary antibodies, the membranes were washed twice with PBS, incubated for 2 Â 10 min in 150 mM glycine pH 2.5, 0.4% SDS, neutralized with 1 M Tris -HCl pH 6.8 and washed three times with PBS and reprobed with an antiactin-antibody. Chemiluminescent reaction was performed to detect the signals.
Filter retardation assay
Wt Hoxd13 and mutated Hoxd13 (þ21 Ala) were expressed as maltose binding protein (MBP) fusion proteins in E. coli and affinity purified on amylose resin according to manufacturer's instructions (NEB, Frankfurt am Main, Germany). For in vitro aggregation experiments 7.2 mM of MBP-Hoxwt and MBP-Hox þ21 Ala were incubated with FaktorXa at 378C. At indicated times, reactions were stopped by the addition of an equal volume of 4% SDS/100 mM DTT and boiling for 5 min. Aliquots corresponding to 11 mg of MBP fusion protein were diluted into 0.1 ml 0.1% SDS and analyzed by filter retardation assay as described previously (29) . Captured aggregates were detected by incubation with anti-Hoxd13 serum (1 : 1500), followed by incubation with alkaline phosphatase conjugated anti-rabbit secondary antibody and the fluorescent substrate attophos.
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Mice Spdh mice were obtained from the Jackson Lab, Bar Harbor, ME, USA. Spdh is a spontaneous mutation that arose in a B6C3 mouse and was subsequently maintained on this background (22) . Analysis of the phenotype was performed on the same background. Mutant offspring was generated by breeding spdh/þ with spdh/þ mice. For analysis of mutant embryos, timed matings were produced and noon of the day the vaginal plug was observed was counted as day 0.5 of gestation. DNA from liver or tail tips served for genotyping. Genotyping of mice was performed as described (22) .
